تداخلات بالونوسيترون

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة البلادونا والأفيون، التداخلات الدوائية)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة أمفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (نشرة أمفيتامين وديكستروأمفيتامين، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (نشرة أوكسيكودون، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوكسيمورفون، التداخلات الدوائية)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوليسيريدين، التداخلات الدوائية)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة باراسيتامول وكودايين، الاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بروميثازين وكودايين، التداخلات الدوائية)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بنتازوسين ونالوكسون، الاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين، التداخلات الدوائية)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، التداخلات الدوائية)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بوتورفانول، الاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (نشرة ديكستروأمفيتامين، التحذيرات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ريميفنتانيل، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة زيبراسيدون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة فنتانيل، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة كودايين، التداخلات الدوائية)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة ليفورفانول، الاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة مورفين، التداخلات الدوائية)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (نشرة ميتاكسالون، التداخلات الدوائية)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ميثادون، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ميثامفيتامين، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون، التداخلات الدوائية)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وإيبوبروفين، الاحتياطات)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وباراسيتامول، الاحتياطات)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وكلورفينيرامين، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وهوماتروبين، التداخلات الدوائية)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدرومورفون، التداخلات الدوائية)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (نشرة نالبوفين، التداخلات الدوائية)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (نشرة أوكسيكودون وباراسيتامول، التداخلات الدوائية)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (نشرة بالونوسيترون، التحذيرات والاحتياطات)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (نشرة فينترمين، التحذيرات والاحتياطات)